Skip to content

MR-HIFU for Non-invasive Thermal Therapy of Facet-Joint Syndrome:

Evaluation of Sonalleve MR-HIFU for Non-invasive Thermal Therapy of Facet-Joint Syndrome: Feasibility and Safety Clinical Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05436873
Acronym
HIFU-FACET
Enrollment
10
Registered
2022-06-29
Start date
2022-06-10
Completion date
2024-06-30
Last updated
2022-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facet Joint Syndrome

Brief summary

Patients suffering from facet-joint-syndrome associated with lower-back pain will be treated with MRI-guided High Intensity Focused Ultrasound thermal therapy for pain relief.

Detailed description

Patients with diagnosed facet-joint-syndrome are suffering from severe pain in the respective regions, mainly lower-back pain. Eligible patients will be treated with High Intensity Focused Ultrasound (HIFU) under MRI control. The control by MRI assures on the one hand the correct selection of area to be sonicated and monitors in parallel the temperature, reached in the target area. The aim is to thermally ablate facet joint and/or medial branch nerves at lumbar spine. Ablation is deemed to be feasible and successful if temperatures of at least 57°C are reached at the target. The entire procedure will be done under anaesthesia.

Interventions

DEVICEMR-HIFU

MRI guided High Intensity Focused Ultrasound sonication.

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Universitätsklinikum Köln
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

There is only 1 treatment arm, as this is a feasibility study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* chronic low back pain * clinical diagnosis of Lumbar Facet Joint Syndrome * eligible for MRI and MR-HIFU session * eligible for general anaesthesia * intact skin and soft tissue over treatment zone * facet joint anatomy clearly identifiable * patients must be able to discontinue all pain relief medication for a minimum of 48 hours prior to baseline assessment * patients able to provide consent for the study

Exclusion criteria

* spinal implants * treatment target zone \< 10 mm from the skin * pregnant female patients * breastfeeding female patients * body weight \> 140 kg * systemic and/or local infections * moderate to high grade of spinal instability * MRI contrast agent contraindication * any MRI-unsafe implant or pacemaker * facet joint anatomy which is not targetable or reachable due to scars, surgical clips, implants, or prosthesis in the planned beam path of the ultrasound beam

Design outcomes

Primary

MeasureTime frameDescription
Feasibility: planned temperature (57°C) achieved at target area of sonicationtreatment day (4 hours)Temperatures achieved at the intended treatment location during MR-HIFU treatments

Secondary

MeasureTime frameDescription
safety of entire procedure180 daysFrequency and severity of adverse events associated with use of the Sonalleve MR-HIFU system
Pain reduction after study treatment180 dayspain reduction as shown in VAS and change in frequency/type/dosing of pain relief medication
change in Quality of Life (QoL) assessed via Quality of Life Questionnaire180 daysThe change in QoL scores throughout study participation \[as higher values, as better quality of Life\]
comparison of contrast in MRI before and after treatment180 daysQualitative analysis of the change in image tissue contrast in MRI images taken prior, during and after the treatment. This is a visual evaluation only.

Countries

Germany

Contacts

Primary ContactChristian Krauss, PhD
ChristianKrauss@uk-koeln.de
Backup ContactHolger Gruell, Prof.
Holger.Gruell@uk-koeln.de+49221

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026